Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

May

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Behind the Scenes of the 2026 ASCO Annual Meeting

First-Line Sunvozertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations

FDA Approves Durvalumab Plus BCG for High-Risk NMIBC

Local Radiotherapy May Help Control Oligometastatic Breast Cancer

TAILORx and RxPONDER Trials Shift to a Discovery Platform